关于 证券代码:600252 证券简称:中恒集团 国泰海通证券股份有限公司 广西梧州中恒集团股份有限公司 在本财务顾问报告中,除非另有说明,下列简称具有如下含义: 独立财务顾问报告 二〇二五年四月 | 一、释义 | | --- | | 二、声明………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 3 | | 三、基本假设 | | 四、限制性股票激励计划已履行的相关审批程序 | | 五、独立财务顾问意见……………………………………………………………………………………………………… 7 | | (一) 第三个解除限售期解除限售条件未成就的说明 | | (二)回购注销部分限制性股票相关事项的说明 | | (三)结论性意见 11 | 目 录 1 一、释义 回购注销部分限制性股票 之 2021年限制性股票激励计划第三个解除限售期 解除限售条件未成就及 (五)本独立财务顾问本着勤勉、审慎、对上市公司全体股东尽责的态度 ...

北京大成律师事务所 北京大成律师事务所 关于广西梧州中恒集团股份有限公司 2021 年限制性股票激励计划回购注销部分限制性股票 事项的 法律意见书 北京市朝阳区朝阳门南大街 10 号兆泰国际中心Ｂ座 16-21 层（100020) 16-21F, Tower B, ZT International Center, No. 10, Chaoyangmen Nandajie Chaoyang District, 100020, Beijing, China Tel: +86 10-58137799 Fax: +86 10-58137788 关于广西梧州中恒集团股份有限公司 2021 年限制性股票激励计划回购注销部分限制性股票事项的 法律意见书 致:广西梧州中恒集团股份有限公司 北京大成律师事务所(以下简称"本所")接受广西梧州中恒集团股份有限公司(以 下简称"中恒集团"或"公司")的委托,担任中恒集团 2021年限制性股票激励计划(以 下简称"本次激励计划")的专项法律顾问,根据《中华人民共和国公司法》(以下简称 "《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理 委员会(以下 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥742,032,480.62, a decrease of 7.92% compared to ¥805,896,093.75 in the same period last year[3]. - Net profit attributable to shareholders was ¥18,267,108.80, down 66.61% from ¥54,711,195.13 year-on-year[3]. - Basic and diluted earnings per share were both ¥0.0055, representing a decrease of 65.63% from ¥0.0160 in the same period last year[3]. - The decline in net profit was primarily due to decreased revenue and gross margin from core products, as well as reduced interest income from deposits[5]. - The company reported a net profit margin decline due to increased sales and management expenses, with sales expenses at CNY 109,489,235.98 compared to CNY 209,029,038.08 in the previous year[22]. - Net profit for Q1 2025 was ¥5.43 million, down from ¥52.08 million in Q1 2024, representing a decline of approximately 89.6%[23]. - Total revenue from operating activities in Q1 2025 was ¥742.18 million, compared to ¥1.02 billion in Q1 2024, indicating a decrease of about 27.1%[26]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥78,876,401.34, a decline of 319.95% compared to ¥35,861,697.83 in the previous year[3]. - The net cash flow from operating activities for Q1 2025 was negative at ¥78.88 million, contrasting with a positive cash flow of ¥35.86 million in Q1 2024[27]. - Cash and cash equivalents as of March 31, 2025, were CNY 4,063,149,941.05, slightly up from CNY 4,054,748,826.46 at the end of 2024[17]. - Cash and cash equivalents at the end of Q1 2025 amounted to approximately ¥4.01 billion, an increase from ¥2.96 billion at the end of Q1 2024[27]. - The company generated ¥561.23 million in cash inflows from financing activities in Q1 2025, compared to ¥323.72 million in Q1 2024, reflecting an increase of about 73.5%[27]. - Investment activities resulted in a net cash outflow of approximately ¥2.06 million in Q1 2025, contrasting with a net inflow of ¥104.72 million in Q1 2024[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,975,883,501.57, a slight decrease of 0.03% from ¥10,979,027,992.83 at the end of the previous year[3]. - Total liabilities increased to CNY 3,500,477,240.12 from CNY 3,464,282,597.71, reflecting an increase of 1.0%[19]. - Shareholders' equity attributable to shareholders was ¥5,992,667,376.83, down 0.50% from ¥6,022,749,391.71 at the end of the previous year[3]. - Shareholders' equity decreased to CNY 7,475,406,261.45 from CNY 7,514,745,395.12, a decline of 0.5%[20]. Share Repurchase and Equity Transactions - The company plans to repurchase shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million[9]. - As of April 10, 2025, the company has repurchased 5,025,200 shares, representing 0.1498% of the total share capital, at a total cost of RMB 11,628,944.00[10]. - The company has completed the cancellation of 40,976,146 shares as part of its share repurchase program[11]. - The company has successfully transferred 18% equity in Guangxi United Asset Management Co., Ltd. for a total consideration of RMB 194,112,400.00, receiving 70% of the payment amounting to RMB 135,878,680.00[12]. - The company has received a total of RMB 427,233,906.20 in compensation from the Zhaoqing High-tech Zone Land Reserve Center, with an outstanding principal of RMB 391,000,000.00[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were CNY 734,544,101.77, down from CNY 796,062,123.50 in Q1 2024, reflecting a reduction of 7.7%[22]. - Operating costs included CNY 522,222,922.64 in operating expenses, which increased from CNY 489,514,549.97 in the previous year, marking a rise of 6.5%[22]. - R&D expenses for Q1 2025 were approximately ¥25.56 million, a slight decrease from ¥25.93 million in Q1 2024[23]. - The company reported a significant decrease in interest income, which fell to ¥18.48 million in Q1 2025 from ¥28.57 million in Q1 2024[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 122,297[6]. - The weighted average return on equity decreased by 0.53 percentage points to 0.30% from 0.83%[3].

法律意见书 国浩律师（南宁）事务所 关于广西梧州中恒集团股份有限公司 2024 年年度股东大会的法律意见书 法律意见书 2012 年第五次临时股东大会的 国浩律师（南宁）意字(2024)第 5052-7 号 致：广西梧州中恒集团股份有限公司 2012 年第五次临时股东大会的 法律意见书 国浩律师（南宁）事务所受广西梧州中恒集团股份有限公司（以下简 称"公司"）的委托，指派覃锦律师、刘卓昀律师（以下简称"本律师"） 作为公司召开 2024 年年度股东大会（以下简称"本次股东大会"或"会 议"）的专项法律顾问，对本次股东大会的召开全过程进行见证并出具法 律意见。 为出具法律意见，本律师出席了本次股东大会的会议，并审查了公司 提供的有关会议文件、资料。公司承诺：其已向本律师提供了出具法律意 见所必须的、真实的书面材料。本律师已证实书面材料的副本、复印件与 正本、原件一致。 基于对上述文件、资料的审查，本律师根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司股东会规则》《广西梧州中恒集团 股份有限公司章程》（以下简称《公司章程》）等有关规定，按照律师行 业公认的业务标准、道德规范和勤勉尽责的精神，对本次 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-46 广西梧州中恒集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 4 月 28 日 (二) 股东大会召开的地点：广西南宁市江南区高岭路 100 号办公楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1.出席会议的股东和代理人人数 | 657 | | --- | --- | | 2.出席会议的股东所持有表决权的股份总数（股） | 1,012,926,058 | | 3.出席会议的股东所持有表决权股份数占公司有表决权股 | 30.7422 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由广西梧州中恒集团股份有限公司（以下简称"中恒集团"或 "公司"）董事会召集，会议由公司董事长杨金海先生主持。 ...

Core Viewpoint - The National Medical Products Administration announced that two batches of toothpaste produced by Tianqi Family Chemical Industry Co., Ltd. were found to have excessive total bacterial counts, exceeding the limit by 37 times and 1279 times respectively [2][3]. Group 1: Product Quality Issues - Two batches of Tianqi toothpaste were reported with total bacterial counts of 19,000 CFU/g and 640,000 CFU/g, while the allowable limit is 500 CFU/g [3]. - The specific products involved are "Tianqi Anti-Bleeding Toothpaste (120g)" and "Tianqi Anti-Heat Toothpaste (Refreshing Wild Chrysanthemum Flavor) (165g)" [3]. Group 2: Company Response and Market Presence - As of April 28, the official flagship store of Tianqi did not list the involved products for sale [6]. - The company stated that they would relay the inquiry to a specialist, while the board secretary office of Zhongheng Group acknowledged awareness of the issue but required an email for further communication [7]. Group 3: Company Financial Performance - Zhongheng Group, the parent company of Tianqi, reported a revenue decline of 26.67% to 2.271 billion yuan and a net loss of 377 million yuan for 2024, marking a significant downturn from profitability [10]. - Tianqi Family Chemical Industry Co., Ltd. specifically recorded a net loss of 38.72 million yuan in 2024 [10]. Group 4: Ownership Structure - Zhongheng Group holds a 55.44% stake in Tianqi Family Chemical Industry, with the second-largest shareholder being Guangxi Guishun Investment Management Co., Ltd., holding 44.56% [7]. - Guangxi Investment Group Co., Ltd. also has a 25.62% stake in Zhongheng Group, indicating a strong connection to state-owned enterprises [8].

Core Viewpoint - The decline of Tianqi toothpaste, once a leading brand in the Chinese market, is attributed to quality issues and management challenges following its acquisition by Zhongheng Group, highlighting the difficulties traditional brands face in maintaining quality and relevance in a competitive market [5][10]. Group 1: Brand History and Market Position - Tianqi toothpaste, launched in 1974, became popular due to its unique formulation using traditional Chinese medicine, achieving a market share of 15% at its peak [5]. - In 2004, Tianqi toothpaste's sales reached 400 million units, generating revenue of 1 billion yuan, positioning it among the top four toothpaste brands in China [2]. Group 2: Quality Issues - In April 2025, the National Medical Products Administration reported that two variants of Tianqi toothpaste had bacterial counts exceeding standards by 1280 times and 38 times, respectively [6]. - The "Panic of Fire" variant contained 19,000 CFU per gram, far exceeding the national limit of 15 CFU/g, contrasting sharply with its previous reputation for quality [6]. Group 3: Corporate Changes and Challenges - After a series of ownership changes, Zhongheng Group acquired Tianqi's parent company in 2021, aiming to revitalize the brand through a dual focus on pharmaceuticals and daily chemicals [6]. - Despite efforts to expand the product line, including mouthwash and laundry detergent, the market share of core products has not recovered, with the daily chemical segment contributing less than 20% to total revenue [7]. Group 4: Financial Performance - In 2024, Zhongheng Group reported revenue of 2.27 billion yuan, a decline of 26.7%, and a net loss of 377 million yuan, marking a significant downturn from profitability [8]. - The pharmaceutical segment faced challenges, with a 40% price drop in its flagship product, leading to an 8 percentage point decrease in gross margin [8]. Group 5: Future Outlook and Strategic Questions - Zhongheng Group holds 4.1 billion yuan in cash and has a debt ratio of 31.55%, but faces significant challenges in transforming its business model [9]. - The company must address quality trust issues and appeal to younger consumers while navigating the pressures of price reductions in the pharmaceutical sector [9][10]. - Key questions remain regarding how to restore brand health, manage product recalls, and implement modern production standards in the daily chemical sector [10].

证券代码：600252 证券简称：中恒集团 公告编号：临2025-43 广西梧州中恒集团股份有限公司 关于召开2024年 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025年5月7日（星期三）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com） 登录新浪财经APP 搜索【信披】查看更多考评等级 会议召开方式：上证路演中心网络文字互动 投资者可于2025年4月25日（星期五）至5月6日（星期二）16:00前登录上证路演中心网站首页点击"提 问预征集"栏目或通过广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）邮箱 （zh600252@126.com）进行提问。公司将在业绩说明会上对投资者普遍关注的问题进行回答。 公司已于2025年3月29日披露《广西梧州中恒集团股份有限公司2024年年度报告》及其摘要，为便于广 大投资者更全面深入地了解公司2024年年度经营成果、财务状况，公司计划于 ...